Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials

Int J Impot Res. 2021 Apr;33(3):383-385. doi: 10.1038/s41443-020-0258-0. Epub 2020 Mar 17.

Authors

Ioannis Mykoniatis¹, Dimitrios Kalyvianakis², Paraskevi Kapoteli^{2

3}, Filimon Zilotis^{2

3}, Agrippina Fournaraki^{2

3}, Evangelos Poulios^{2

3}, Dimitrios Hatzichristou^{2

3}

Affiliations

¹ 1st Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece. g_mikoniatis@hotmail.com.
² 1st Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Institute for the Study of Urological Diseases, Thessaloniki, Greece.

PMID: 32203424
DOI: 10.1038/s41443-020-0258-0

No abstract available

Publication types

Letter

MeSH terms

Cyclic Nucleotide Phosphodiesterases, Type 5
Data Analysis
Erectile Dysfunction* / drug therapy
High-Energy Shock Waves*
Humans
Male
Phosphodiesterase 5 Inhibitors / therapeutic use
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Phosphodiesterase 5 Inhibitors
Cyclic Nucleotide Phosphodiesterases, Type 5